Chromium Controls Glucose Metabolism, Benefits Diabetics

Chromium Controls Glucose Metabolism, Benefits Diabetics

BATON ROUGE, La. & ATHENS, GreeceTwonew proprietary studies on chromium picolinate shed light on the mineralsability to influence blood sugar, according to releases from Nutrition 21(www.nutrition21.com).

In the first study, conducted at the Pennington BiomedicalResearch Center in Baton Rouge, La., and presented at this years Meeting ofthe European Association for the Study of Diabetes (EASD) in Athens, Greece,researchers found in vitro administration of chromium picolinate (as Chromax®,from Nutrition 21) to skeletal muscle cells increased levels of the metabolicenzyme AMP-activated protein kinase (AMPK), improving energy balance and insulinfunction.

In the second study, co-administration of chromium picolinateand biotin (as Diachrome®, from Nutrition 21) and prescription treatmentregimens to Type II diabetics produced an 0.7 percent to 1.9 percent pointreduction in HbA1c levels as well as significantly reduced insulin resistance.Results of the double blind, randomized, placebo-controlled, multi-center,12-week study were also presented at the EASD conference.

According to Nutrition 21, a new agreement with XLHealth willmake Diachrome available to physicians participating in the Center for Medicareand Medicaid (CMS) sponsored-Medicare Health Support (formerly known as theChronic Care Improvement Program) program, to treat Medicare patients inTennessee who have diabetes and heart failure.

We are confident that these new scientific findings and thetreatment success that will be seen in the XLHealth Medicare Health Supportprogram will fuel further adoption of Diachrome in diabetes care, said Gail Montgomery, president and chief executive officer(CEO) of Nutrition 21.